Janney Montgomery Scott LLC Decreases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Janney Montgomery Scott LLC lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRLFree Report) by 2.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,706 shares of the medical research company’s stock after selling 1,225 shares during the period. Janney Montgomery Scott LLC’s holdings in Charles River Laboratories International were worth $10,332,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of CRL. VisionPoint Advisory Group LLC boosted its position in shares of Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after acquiring an additional 74 shares in the last quarter. Headlands Technologies LLC purchased a new stake in Charles River Laboratories International during the third quarter worth approximately $37,000. Operose Advisors LLC purchased a new position in Charles River Laboratories International in the third quarter valued at approximately $42,000. Venturi Wealth Management LLC raised its holdings in Charles River Laboratories International by 74.7% during the third quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock worth $51,000 after purchasing an additional 112 shares in the last quarter. Finally, Provence Wealth Management Group purchased a new stake in shares of Charles River Laboratories International during the 3rd quarter worth approximately $57,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 1.4 %

NYSE:CRL opened at $221.61 on Friday. Charles River Laboratories International, Inc. has a 12-month low of $161.65 and a 12-month high of $275.00. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73. The stock’s 50 day simple moving average is $246.35 and its 200-day simple moving average is $227.90. The firm has a market cap of $11.42 billion, a P/E ratio of 26.07, a PEG ratio of 1.72 and a beta of 1.44.

Charles River Laboratories International (NYSE:CRLGet Free Report) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.05 by $0.22. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $997.24 million. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 11 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In related news, VP William D. Barbo sold 4,050 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the sale, the vice president now owns 22,879 shares in the company, valued at $5,685,431.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, EVP Victoria L. Creamer sold 5,000 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the transaction, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at approximately $3,437,635. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP William D. Barbo sold 4,050 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the sale, the vice president now owns 22,879 shares of the company’s stock, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. Insiders have sold a total of 10,354 shares of company stock worth $2,570,894 over the last ninety days. 1.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. UBS Group increased their target price on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. Evercore ISI lifted their target price on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a research report on Thursday, February 15th. Citigroup upped their target price on Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research report on Thursday, February 15th. Argus lifted their price target on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, March 18th. Finally, JPMorgan Chase & Co. increased their price objective on Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, Charles River Laboratories International has an average rating of “Moderate Buy” and a consensus target price of $255.27.

Get Our Latest Stock Report on CRL

About Charles River Laboratories International

(Free Report)

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Featured Stories

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLFree Report).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.